The global preimplantationgenetic testing market was
valued at USD 129.3 million in 2015 and is expected to reach a value of USD
221.1 million by 2024, according to a new report by Grand View Research, Inc.
Growth in number of offspring born with inherited conditions is a high impact
rendering factor for growth of this market. Emergence of preimplantation
genetic diagnosis for detection of nearly all genetically inherited conditions
enable couples, who are carriers of such conditions, screen their embryos
before transferring to uterus and this is the primary driver of this industry.
Increase in
adoption of IVF as a result of pregnancy-related complications is anticipated
to drive demand for preimplantation genetic testing services. Women who are
undergoing IVF are expected to undergo PGT cycles for prevention of inheritance
of chromosomal abnormalities by offspring, which as a consequence is augmenting
growth.
Growth in
demand for these tests can be ascribed to the increase in rate of infertility
due to environmental and lifestyle factors, which in turn, emphasizes the need
for development in this vertical.
Full research report on Preimplantation Genetic Testing Market analysis:
http://www.grandviewresearch.com/industry-analysis/preimplantation-genetic-testing-pgt-market
Further Key Findings From the Study Suggest:
·
Preimplantation genetic testing is
available for different types of services, which include X-linked diseases,
Human Leukocyte Antigen (HLA) typing, chromosomal abnormalities, freeze embryo
testing, aneuploidy screening, detection of serious late-onset diseases, and
gender selection. Preimplantation genetic testing for chromosomal abnormalities
accounted for approximately 29% of the market share due to advancements in its
screening by the use of noninvasive prenatal testing, which employs cell-free
DNA for early detection of chromosomal abnormalities, such as Patau syndrome,
Edwards syndrome, and Down syndrome.
·
This technology has various applications.
Amongst all the applications, embryo HLA typing for stem cell therapy dominated
with a share of over 30%. This largest share can be attributed to the benefits
associated with the use of PGD for identification of HLA compatible embryos for
stem cell therapy.
·
Although usage of these tests for inherited
chromosomal disease is observed to have less penetration in the current
scenario, it is expected to witness tremendous growth in the coming years due
to increasing adoption rate of this service for detection of inherited genomic
anomalies, such as sickle cell anemia and Huntington’s disease.
·
Europe accounted for the largest share with
respect to revenue as a result of growing awareness about the scope of these
diagnostic services for delivering genetically fit offspring. Also, developed
infrastructure, rising investments by governmental bodies, and presence of key
players in this region, collectively encourages growth of this industry in this
region.
·
Some of the key players that have
commercialized PGT services include F. Hoffmann-La Roche AG; Genea Limited;
Quest Diagnostics, Illumina, Inc.; Natera, Inc; CooperSurgical, Inc; LabCorp;
California Pacific Medical Center; Thermo Fisher Scientific, Inc; Igenomix;
Reproductive Genetic Innovations, LLC; CombiMatrix; Good Start Genetics, Inc;
Bioarray S.L; and Reproductive Health Science Ltd.
·
These key participants are actively
involved in the R&D initiatives for development of novel PGT services.
Partnership between entities and acquisition of small companies by major
companies in order to reinforce its status in the market as well as to expand
its product catalog for this vertical is expected boost revenue generation in
preimplantation genetic diagnostics.
·
For instance, In December 2015, Natera,
entered into a partnership with MedGenome, provider of genomic solutions for
personalized healthcare in India. As per this partnership, MedGenome will be
allowed to use the Panorama noninvasive prenatal test in its research
laboratory. As a result, MedGenome becomes the first provider of this service
in India.
View more reports of this category by Grand
View Research at: https://www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented
preimplantation genetic testing market on the basis of application, type, and
region:
Type Outlook
(Market Revenue in USD Million, 2013 - 2024)
·
Chromosomal Abnormalities
·
X-linked Diseases
·
Freeze Embryo Testing
·
Aneuploidy Screening
·
HLA Typing
·
Other PGT Types
Application
Outlook (Revenue in USD Million, 2013 - 2024)
·
Embryo HLA Typing for Stem Cell Therapy
·
IVF Prognosis
·
Late-Onset Genetic Disorders
·
Inherited Genetic Disease
·
Others
Regional
Outlook (Market Revenue in USD Million, 2013 - 2025)
·
North America
o
U.S.
o
Canada
·
Europe
o
Germany
o
UK
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
o
Mexico
·
Middle East and Africa
o
South Africa
Access press release by
Grand View Research: https://www.grandviewresearch.com/press-release/global-preimplantation-genetic-testing-pgt-market
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
